Positive Results for Quillaja-Based Vaccine Adjuvant in K-State's CSF Vaccine
Q-Vant Biosciences announced "very positive" results comparing Q-Vant's sustainable saponin-based adjuvant, Q-VET-S, to Croda's Quil-A adjuvant. These results were obtained through a collaborative study with Kansas State University, utilizing their subunit classic swine fever (CSF) vaccine.
The CSF vaccine was developed by Kansas State professor Jishu Shi. He also serves as the director of the Center for Vaccine Evaluation, where he and his team are working on novel vaccine and diagnostic strategies aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF), and other emerging viral diseases of swine, according to a release.
"The development of Q-VET-S and its proven effect marks a major milestone in the field of vaccine adjuvants," Juan Jose Albarran, chief commercial officer of Q-Vant Biosciences, said in a release. "Our cutting-edge technology not only ensures a reliable supply for the pharmaceutical sector but also addresses the environmental concerns associated with Quillaja Saponaria harvesting. By focusing on sustainability, we are playing a significant role in protecting Chile's forests while simultaneously advancing global animal and human health."
